.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Baxter
Argus Health
Cipla
Dow
Fuji
Medtronic
Queensland Health
Boehringer Ingelheim

Generated: July 26, 2017

DrugPatentWatch Database Preview

NOVARTIS Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS, and when can generic versions of NOVARTIS drugs launch?

NOVARTIS has two hundred and thirty-six approved drugs.

There are one hundred and ninety-two US patents protecting NOVARTIS drugs and there have been eight Paragraph IV challenges on NOVARTIS drugs in the past three years.

There are three thousand three hundred and eighty-nine patent family members on NOVARTIS drugs in seventy-nine countries.

Summary for Applicant: NOVARTIS

Patents:192
Tradenames:195
Ingredients:164
NDAs:236
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
TEKAMLO
aliskiren hemifumarate; amlodipine besylate
TABLET;ORAL022545-001Aug 26, 2010DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Novartis
MIOCHOL
acetylcholine chloride
FOR SOLUTION;OPHTHALMIC016211-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-001Mar 30, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis
MYFORTIC
mycophenolic acid
TABLET, DELAYED RELEASE;ORAL050791-002Feb 27, 2004ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-002Oct 11, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
NEORAL
cyclosporine
CAPSULE;ORAL050715-001Jul 14, 1995► Subscribe► Subscribe
Novartis Pharms Corp
CIPRO HC
ciprofloxacin hydrochloride; hydrocortisone
SUSPENSION/DROPS;OTIC020805-001Feb 10, 1998► Subscribe► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 2010► Subscribe► Subscribe
Novartis
FOCALIN XR
dexmethylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021802-006Aug 11, 2010► Subscribe► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-003Dec 15, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for NOVARTIS drugs

Drugname Dosage Strength Tradename Submissiondate
everolimus
Tablets for Oral Suspension2 mg, 3 mg and 5 mg
AFINITOR DISPERZ
12/30/2016
travoprost
Ophthalmic Solution0.003%
IZBA
12/30/2015
nepafenac
Ophthalmic Suspension0.3%
ILEVRO
12/21/2015
deferasirox
Tablets180 mg
JADENU
10/23/2015
deferasirox
Tablets90 mg and 360 mg
JADENU
10/19/2015
olopatadine hydrochloride
Ophthalmic Solution0.7%
PAZEO
9/10/2015
everolimus
Tablets2.5 mg, 5 mg, and 7.5 mg
AFINITOR
12/10/2014
fingolimod
Capsules0.5 mg
GILENYA
9/22/2014
everolimus
Tablets10 mg
AFINITOR
6/18/2014
difluprednate
Ophthalmic Emulsion0.05%
DUREZOL
5/1/2014
eltrombopag olamine
Tablets12.5 mg and 25 mg
PROMACTA
2/4/2014
imatinib mesylate
Capsules400 mg
GLEEVEC
1/24/2014
eltrombopag olamine
Tablets50 mg and 75 mg
PROMACTA
1/7/2014
everolimus
Tablets0.25 mg, 0.5 mg, and 0.75 mg
ZORTRESS
9/30/2013
nilotinib
Capsules150 mg and 200 mg
TASIGNA
1/29/2013
rivastigmine
Transdermal System Extended-release13.3 mg/24 hr
EXELON
1/22/2013
ciprofloxacin and dexamethasone
Otic Suspension0.3%/0.1%
CIPRODEX
7/31/2012
moxifloxacin hydrochloride
Ophthalmic Solution10.5%
MOXEZA
2/29/2012
zoledronic acid
Injection4 mg/100 mg, 100 mL vial
ZOMETA
1/31/2012
argatroban in sodium chloride
Injection1 mg/mL, 50 mL vials
ARGATROBAN
12/16/2011
deferasirox
Tablets125 mg, 250 mg, and 500 mg
EXJADE
10/28/2011
dexmethylphenidate
Extended-release capsules25 mg
FOCALIN XR
9/30/2011
dexmethylphenidate
Extended-release capsules35 mg
FOCALIN XR
9/29/2011
lapatinib ditosylate
Tablets250 mg
TYKERB
3/14/2011
dexmethyphenidate hydrochloride
Extended-release Capsule40 mg
FOCALIN XR
12/20/2010
dexmethylphenidate hydrochloride
Extended-release Capsule30 mg
FOCALIN XR
12/15/2010
amlodipine, hydrochlorothiazide and valsartan
Tablets10 mg/12.5 mg/160 mg
EXFORGE HCT
10/22/2009
amlodipine, hydrochlorothiazide and valsartan
Tablets5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 m
EXFORGE HCT
9/14/2009
olopatadine hydrochloride
Nasal Spray0.665 mg/ Spray
PATANASE
6/29/2009
tobramycin
Inhalation Solution300 mg/5 mL
TOBI
6/29/2009
mycophenolic acid
Delayed-release Tablets180 mg
MYFORTIC
6/4/2009
travoprost (preserved)
Ophthalmic Solution0.00%
TRAVATAN Z
2/19/2009
mycophenolic acid
Delayed-release Tablets360 mg
MYFORTIC
2/2/2009
olopatadine hydrochloride
Ophthalmic Solution0.20%
PATADAY
9/8/2008
zoledronic acid
Injection0.05 mg/mL, 100 mL vial
RECLAST
8/29/2008
zoledronic acid
Injection0.8 mg (base) /mL
ZOMETA
6/11/2008
fluvastatin
Capsules20 mg and 40 mg
LESCOL
6/4/2008
amlodipine besylate and valsartan
Tablets5 mg/320 mg
EXFORGE
11/26/2007
amlodipine besylate and valsartan
Tablets10 mg/320 mg
EXFORGE
11/9/2007
amlodipine besylate and valsartan
Tablets5 mg/160 mg
EXFORGE
10/22/2007
amlodipine besylate and valsartan
Tablets10 mg/160 mg
EXFORGE
10/1/2007
argatroban
Injection100 mg/mL, 2.5 mL vials
ARGATROBAN
9/24/2007
metformin hydrochloride
Extended-release Capsules10 mg
RITALIN LA
5/21/2007
dexmethylphenidate hydrochloride
Extended-release Capsules15 mg
FOCALIN XR
5/14/2007
dexmethylphenidate hydrochloride
Extended-release Capsules5mg, 10mg and 20 mg
FOCALIN XR
3/30/2007
fluvastatin sodium
Extended-release Tablets80 mg
LESCOL XL
3/15/2007
imatinib mesylate
Tablets100 mg and 400 mg
GLEEVEC
3/12/2007
valsartan and hydrochlorothiazide
Tablets320 mg/12.5 mg and 320 mg/25 mg
DIOVAN HCT
2/7/2007
oxcarbazepine
Oral Suspension300 mg/5 mL
TRILEPTAL
12/26/2006
amlodipine besylate and benazepril hydrochloride
Capsules5 mg/40 mg and 10 mg/40 mg
LOTREL
11/17/2006
metformin hydrochloride
Extended-release Capsules20 mg, 30 mg and 40 mg
RITALIN LA
8/21/2006
olopatadine hydrochloride
Ophthalmic Solution0.10%
PATANOL
7/17/2006
oxcarbazepine
Tablets150 mg, 300 mg and 600 mg
TRILEPTAL
5/5/2006
letrozole
Tablets2.5 mg
FEMARA
3/2/2006
carbamazepine
Extended-release Tablets100 mg
TEGRETOL-XR
12/30/2005
moxifloxacin hydrochloride
Ophthalmic0.50%
VIGAMOX
12/22/2005
valsartan and hydrochlorothiazide
Tablets80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg
DIOVAN HCT
12/2/2005
famciclovir
Tablets125 mg, 250 mg and 500 mg
FAMVIR
12/28/2004
valsartan
Tablets40 mg, 80 mg,160 mg
DIOVAN
12/28/2004
nateglinide
Tablets60 mg and 120 mg
STARLIX
12/22/2004
ondansetron hydrochloride
Oral Solution4 mg/5 mL
ZOFRAN
12/20/2004
rivastigmine tartrate
Oral Solution2 mg/mL
EXELON
11/5/2004
dexmethylphenidate hydrochloride
Tablets2.5 mg
FOCALIN
7/27/2004
amlodipine besylate and benazepril hydrochloride
Capsules2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg
LOTREL
6/9/2004
dexmethylphenidate hydrochloride
Tablets5 mg and 10 mg
FOCALIN
5/27/2004
rivastigmine tartrate
Capsules1.5 mg, 3 mg, 4.5 mg and 6 mg
EXELON
4/21/2004

Premature patent expirations for NOVARTIS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Novartis

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,557,2102,4-pyrimidinediamine compounds and their uses► Subscribe
6,838,449 Ophthalmic compositions containing galactomannan polymers and borate► Subscribe
8,877,162Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery► Subscribe
5,627,182 .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides► Subscribe
7,709,012Ophthalmic compositions containing a synergistic combination of two polymers► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Drugs

Country Document Number Estimated Expiration
Germany19781690► Subscribe
South Africa200304482► Subscribe
Brazil1100656► Subscribe
Spain2305104► Subscribe
Japan2010270128► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2010Austria► SubscribePRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614
C004Belgium► SubscribePRODUCT NAME: VALSARTAN HYDROCHLOROTHIAZIDUM; NATL. REGISTRATION NO/DATE: 206 IS 250 F 3 19980624; FIRST REGISTRATION: FR 344300.5 19970925
2016000038Germany► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUM SALZKOMPLEX, D.H. TRINATRIUM-(3-((1 S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAT-(S)-3'-METHYL-2'-(PENTANOYL-(2"-(TETRAZOL-5-YLAT)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRAT)-HEMIPENTAHYDRAT.; REGISTRATION NO/DATE: EU/1/15/1058 20151119
2016000037Germany► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, EINSCHLIESSIICH PHARMAZEUTISCH ANNEHMBARER SALZE DAVON; REGISTRATION NO/DATE: EU/1/15/1058 20151119
563Luxembourg► Subscribe91563, EXPIRES: 20231028
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Farmers Insurance
Cerilliant
Argus Health
QuintilesIMS
Healthtrust
Baxter
Accenture
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot